Chunyan Hao

Prof. Dr. Chunyan Hao

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2021 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
XZXiaolin Zhu
Xiaolin Zhu
YZYu Zhang
Yu Zhang
XYXin Yang
Xin Yang
CHChunyan Hao
Chunyan Hao
HDHubin Duan
Hubin Duan
The pathogenesis of neurodegenerative diseases (NDDs) is complex and diverse. Over the decades, our understanding of NDD has been limited to pathological features. However, recent advances in gene sequencing have facilitated elucidation of NDD at a deeper level. Gene editing techniques have uncovered new genetic links to phenotypes, promoted the development of novel treatment strategies and equipped researchers with further means to construct effective cell and animal models. The current review describes the history of evolution of gene editing tools, with the aim of improving overall understanding of this technology, and focuses on the four most common NDD disorders to demonstrate the potential future applications and research directions of gene editing.

27 July 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
XYXin Yang
Xin Yang
XZXiao-Lin Zhu
Xiao-Lin Zhu
JHJia-Qi Hao
Jia-Qi Hao
HBHao Bai
Hao Bai
HDHubin Duan
Hubin Duan
Background: Glioblastoma (GBM) has a high degree of malignancy, aggressiveness and recurrence rate. However, there are limited options available for the treatment of GBM, and they often result in poor prognosis and unsatisfactory outcomes. Materials and methods: In order to identify potential core genes in GBM that may provide new therapeutic insights, we analyzed three gene chips (GSE2223, GSE4290 and GSE50161) screened from the GEO database. Differentially expressed genes (DEG) from the tissues of GBM and normal brain were screened using GEO2R. To determine the functional annotation and pathway of DEG, Gene Ontology (GO) and KEGG pathway enrichment analysis were conducted using DAVID database. Protein interactions of DEG were visualized using PPI network on Cytoscape software. Next, 10 Hub nodes were screened from the differentially expressed network using MCC algorithm on CytoHubba software and subsequently identified as Hub genes. Finally, the relationship between Hub genes and the prognosis of GBM patients was described using GEPIA2 survival analysis web tool. Results: A total of 37 up-regulated and 187 down-regulated genes were identified through microarray analysis. Amongst the 10 Hub genes selected, SV2B appeared to be the only gene associated with poor prognosis in glioblastoma based on the survival analysis. Conclusion: Our study suggests that high expression of SV2B is associated with poor prognosis in GBM patients. Whether SV2B can be used as a new therapeutic target for GBM requires further validation.

23 July 2021 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
JHJia-Qi Hao
Jia-Qi Hao
XHXing-Yue He
Xing-Yue He
XYXin Yang
Xin Yang
YXYouchao Xiao
Youchao Xiao
SDSheng-Qiang Duan
Sheng-Qiang Duan
HDHubin Duan
Hubin Duan

16 April 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
XYXin Yang
Xin Yang
XZXiao-Lin Zhu
Xiao-Lin Zhu
ZWZhuang-Zhuang Wang
Zhuang-Zhuang Wang
HBHao Bai
Hao Bai
HDHubin Duan
Hubin Duan
Background: Glioma is one of the most common malignancies in the central nervous system and has limited effective therapeutic options. Therefore, we sought to identify a suitable target for immunotherapy. Materials and Methods: We screened prognostic genes for glioma in the CGGA database and GSE43378 dataset using survival analysis, receiver operating characteristic (ROC) curves, independent prognostic analysis, and clinical correlation analysis. The results were intersected with immune genes from the ImmPort database through Venn diagrams to obtain likely target genes. The target genes were validated as prognostically relevant immune genes for glioma using survival, ROC curve, independent prognostic, and clinical correlation analyses in samples from the CGGA database and GSE43378 dataset, respectively. We also constructed a nomogram using statistically significant glioma prognostic factors in the CGGA samples and verified their sensitivity and specificity with ROC curves. The functions, pathways, and co-expression-related genes for the glioma target genes were assessed using PPI networks, enrichment analysis, and correlation analysis. The correlation between target gene expression and immune cell infiltration in glioma and the relationship with the survival of glioma patients were investigated using the TIMER database. Finally, target gene expression in normal brain, low-grade glioma, and high-grade glioma tissues was detected using immunohistochemical staining. Results: We identified TNFRSF12A as the target gene. Satisfactory results from survival, ROC curve, independent prognosis, and clinical correlation analyses in the CGGA and GSE43378 samples verified that TNFRSF12A was significantly associated with the prognosis of glioma patients. A nomogram was constructed using glioma prognostic correlates, including TNFRSF12A expression, primary-recurrent-secondary (PRS) type, grade, age, chemotherapy, IDH mutation, and 1p19q co-deletion in CGGA samples with an AUC value of 0.860, which illustrated the accuracy of the prognosis prediction. The results of the TIMER analysis validated the significant correlation of TNFRSF12A with immune cell infiltration and glioma survival. The immunohistochemical staining results verified the progressive up-regulation of TNFRSF12A expression in normal brain, low-grade glioma, and high-grade glioma tissues. Conclusion: We concluded that TNFRSF12A was a viable prognostic biomarker and a potential immunotherapeutic target for glioma.

30 January 2025 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
CZChan Zhao
Chan Zhao
XXXintian Xu
Xintian Xu
CHChunyan Hao
Chunyan Hao
Background: Obesity exerts a significant detrimental impact on cognitive function. The weight-adjusted waist index (WWI) serves as a more precise indicator of visceral obesity that is independent of weight, in contrast to body mass index (BMI). Still, little research has been conducted on the interrelation between WWI and cognitive abilities. This investigation explored the link between WWI and older Americans’ cognitive function.Methods: Utilizing data from the 2011–2014 National Health and Nutrition Examination Cross-Sectional Survey, multiple linear regression analysis was used to assess the influence of WWI on cognitive abilities in those over 60. Three cognitive assessments were administered: the Animal Fluency Test (AFT), the Digit Symbol Substitution Test (DSST), and the Word Learning and Recall Module from the Coalition to Establish a Registry for Alzheimer’s Disease (CERAD). We implemented threshold effects analysis and smoothed curve fitting to elucidate the nonlinear relationship. Additionally, we analyzed subgroups to check for variability.Results: There were 2,762 participants, including1,504 (54.45%) females and 1,258 (45.55%) males. 53.77% of them had completed high school or above, and their average age was 69.05 ± 6.62. After controlling for confounding variables, the improved model predicted a negative connection between WWI and CERAD-Total, AFT, and DSST scores (all p < 0.05). Furthermore, we performed a smoothenable curve fitting between WWI and cognitive function scores, resulting in a nonlinear connection and a threshold saturation effect. We also executed subgroup analyses and interaction tests based on gender, race, educational background, marital status, diabetes, body mass index, alcohol consumption, hypertension, smoking habits, stroke, depression, and sleep quality to assess whether the relationship between WWI and cognitive function was affected by heterogeneity across different population segments. The subgroup analysis found no significant differences in cognitive performance associated with WWI across the various subgroups.Conclusion: Higher WWI levels are associated with impaired cognitive function in Americans aged 60 and older.

1 March 2023 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
JZJun-Jie Zhang
Jun-Jie Zhang
YZYu Zhang
Yu Zhang
QCQian Chen
Qian Chen
QCQi-Ning Chen
Qi-Ning Chen
XYXin Yang
Xin Yang
HDHubin Duan
Hubin Duan
Background: Immune microenvironment serves a vital role in glioma progression, and a large number of studies have found that tumor progression can be reduced to some extent by modulating the immune process in tumors. Materials and Methods: ImmuneScore of each sample in CGGA datasets were calculated with Estimate R package, and samples were grouped by median ImmuneScore values for differential analysis to obtain immune microenvironment differential genes. We further conducted survival analysis, ROC curve analysis, independent prognostic analysis, and clinical correlation analysis on glioma sample genes in CGGA to obtain glioma prognostic genes, and then identified their intersection with immune microenvironment DEGs by Venn tool. The GEPIA and UALCAN databases were used to verify the differential expression of intersecting genes in the glioma and normal brain and to identify our target gene. After validation of their prognostic value, we constructed a nomogram to calculate the risk score and to estimate the accuracy of prognostic model. We mined co-expression genes, enriched functions and pathways, and correlations to immune cell infiltration of unigene with an online database. Finally, we verified the differential expression of FCGBP in glioma by immunohistochemical staining. Results: We finally selected Fc fragment of IgG-binding protein (FCGBP) as our study gene. The prognostic values of FCGBP were validated by a series of analyses. Immunohistochemical staining showed that FCGBP expression increased in gliomas and was up-regulated with the progression of glioma grade. Conclusion: As a key unigene in glioma progression, FCGBP contributes to the regulation of immune microenvironment and has the potential to be a prognostic biomarker and immune targets.